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A B S T R A C T   
Exosomes (EXOs) are naturally occurring nanosized lipid bilayers that can be efficiently used as a drug delivery 
system to carry small pharmaceutical, biological molecules and pass major biological barriers such as the blood- 
brain barrier. It was hypothesized that EXOs derived from human endometrial stem cells (hEnSCs-EXOs) can be 
utilized as a drug carrier to enhance tumor-targeting drugs, especially for those have low solubility and limited 
oral bioactivity. In this study, atorvastatin (Ato) loaded EXOs (AtoEXOs) was prepared and characterized for its 
physical and biological activities in tumor growth suppression of 3 D glioblastoma model. The AtoEXOs were 
obtained in different methods to maximize drug encapsulation efficacy. The characterization of AtoEXOs was 
performed for its size, stability, drug release, and in vitro anti-tumor efficacy evaluated comprising inhibition of 
proliferation, apoptosis induction of tumor cells. Expression of apoptotic genes by Real time PCR, Annexin V/PI, 
tunnel assay was studied after 72 h exposing U87 cells where encapsulated in matrigel in different concentrations 
of AtoEXOs (5, 10 μM). The results showed that the prepared AtoEXOs possessed diameter ranging from 30–150 
nm, satisfying stability and sustainable Ato release rate. The AtoEXOs was up taken by U87 and generated 
significant apoptotic effects while this inhibited tumor growth of U87 cells. Altogether, produced AtoEXOs 
formulation due to its therapeutic efficacy has the potential to be an adaptable approach to treat glioblastoma 
brain tumors.   
1. Introduction 
Glioblastoma (GBM) is highly aggressive and most common form of 
primary brain tumor that has a dire prognosis with high mortality [1–3]. 
Generally, the GBM microenvironment generates under secretion of 
several pro-inflammatory cytokines into a hypoxic condition. In this 
process, pro-inflammatory mediators including interleukin-1β (IL-1β), 
interleukin-6 (IL-6), and also interleukin-8 (IL-8) play key roles in the 
GBM microenvironment [1,2], through activation of their related 
downstream targets such as the JAK-STAT, PI3K-AKT, and 
mitogen-activated protein kinase (MAPK) signaling pathways. During 
GBM progression, the tumor cell proliferation, invasion and also tumor 
angiogenesis arouse a dreadful disorder [3–5]. Meanwhile, conventional 
therapeutic treatments including radiotherapy and chemotherapy are 
strongly restricted in treating GBM due to their toxicity to normal brain 
tissues that have further consequences impact on brain damage and 
decreased quality of life in patients [2,6,7]. Besides, direct application of 
stem cells as a well-known therapy is restricted due to immunological 
barriers and rejection, as well as ethical problems of their preparation 
and concerns for tumor formation at the site of transplantation [8,9]. 
The development of a novel cell-free medical approach with 
tumor-suppressive effects is of great importance. Innovative methods of 
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drug delivery to prevent systemic toxicity of cancer drugs as well as 
targeted drug delivery to the tumor site are among the new approaches 
that are being considered as proper approaches in cancer therapy [10, 
11]. 
Recently the stem cell products as bioactive drug carriers are 
developed to overcome stem cell therapy restrictions [12]. Exosome 
(EXO) as a drug carrier can be a good cell-free material in the field of 
GBM treatment due to being natural product of the body which leads to 
low immune responses. Implantation feature of the EXOs in transport of 
their cargoes to distant targets introduce it as a desirable carrier. The 
EXOs are small nanometer vesicles that originate from the cell mem-
brane and release into the microenvironment of the cells as contain a 
selective set of ligands, receptors, and enzymatic substances [13–15]. 
Moreover, EXOs could drive stimulatory, inhibitory, genetic 
re-programming messages to the target cells through binding and 
internalizing into the cell membrane [16–18]. More interestingly, the 
EXOs are good carriers for delivering medicinal compounds including 
anti-cancer drugs that inhibit inflammatory and angiogenic pathways by 
enzyme-reductase (hydroxymethylglutaryl coenzyme A) inhibitors 
[19–21]. Recently, application of EXOs is developing in regenerative 
medicine due to their advantages, including non-immune rejection, 
homing effect, easy control of their concentration and stability for sus-
tain release of drugs [13,14,22–24]. Besides, statins have been shown 
pleiotropic effects within the specified concentrations and could hinder 
pathways associated with inflammation [25–27]. The exact molecular 
mechanisms of statin effects that can be useful for tumor avoidance 
and/or treatment including apoptosis induction, proliferation inhibition 
are not well cleared [28]. Increasing investigations, both in vitro and in 
vivo, have shown inhibitory effects of statins especially atorvastatin 
(Ato) on tumor cells such as glioblastoma [29–32], melanoma cell line 
[30], breast cancer cell lines [33,34], prostate tumor [35]. Additionally, 
the anti-cancer ability of Ato have also examined in some clinical trials 
[36–38]. It’s suggested that the apoptotic effects of statin can be made 
through several mechanisms consist of upregulation of pro-apoptotic 
protein expression (e.g., Bax, Bim), while downregulation of 
anti-apoptotic proteins (e.g., Bcl-2) [39,40] and activation of caspase 
proteins (caspase 3, 8, 9) [41–43]. The EXOs generally are isolated from 
variety of cell sources such as mesenchymal stem cells, progenitor stem 
cells, adipose derived stem cells and endometrial stem cells. In partic-
ular, EnSC would be used for proposed study due to its immunomodu-
latory function, ease acquisition and minor donor site morbidity which 
has made it as a good candidate for clinical and therapeutic applications. 
Thus, we have taking into account that by isolation of EnSC-derived 
EXOs and their loading with Ato (AtoEXOs) could restrict tumor cell 
growth, pro-apoptosis and apoptosis pathways as well as necrosis in 
GBM model in vitro. 
In this study, EXOs isolated from human EnSC (hEnSC) were used as 
a nano-carrier to load chemotherapeutic drug Ato for GBM treatment. 
The physical and biological characteristics of isolated EXOs were eval-
uated through scanning electron microscopy (SEM), size distribution 
analysis, western blot as well as drug loading release and stability 
measurement during extended time of incubation. The 3 D spheroid 
tumor model was produced using hanging drop of U87 cells in matrigel 
for tumor growth suppression study in different concentrations of 
AtoEXOs and free Ato in vitro. The anti-proliferative effects of AtoEXOs 
were proved by microscopic observation of U87 cell morphology, MTT 
assay and down expression of Ki-67 protein. The annexin/PI flowcy-
tometry and tunnel staining of U87 cells display highest level of 
apoptosis for treated cells with AtoEXOs in both utilized 5 and 10 μM. 
The real time PCR was up-regulated apoptosis-related molecules 
including caspase 3, caspase 8 and caspase 9 in highest levels for 
AtoEXOs conditions. 
2. Materials and methods 
2.1. Materials 
Atorvastatin ([R-(R*, R*)-2-(4-Fluorophenyl)-ß, d-dihydroxy-5-(1- 
methylethyl)-3-Phenyl-4-(Phenylamino) Carbonyl]-1-H-Pyr-role-1- 
heptanoic acid), tween 20, MTT (3-(4,5 Diamethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) were obtained from Sigma Co. (St. 
Louis, USA). A lipophilic fluorescent dyes, 1,1′-dioctadecyl-3,3,3′,3′- 
tetramethylindo-carbocyanine perchlorate (DIL), trizol solution were 
purchased from Invitrogen (Carlsbad, CA, USA). Matrigel matrix from 
Corning, UK, tunnel assay kit from Abcam, UK and cDNA synthesis kit 
from Thermo Scientific Fermentas, USA were obtained. 
2.2. Cultured cells 
Human derived endometrial stem cells (hEnSCs) were isolated from 
donors using laparoscopy procedure according previously described 
protocol [44]. The harvested cells were sub-cultured in 100 mm culture 
dish in a 37 ◦C and 5% CO2 incubator for 2 weeks. The U87 cell line was 
purchased from the Cell Bank of the Pasteur Institute (Tehran, Iran). 
These cells were all grown and maintained Dulbecco’s Modified Eagle 
Medium/F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) 
and 1% penicillin–streptomycin were purchased from Scotland (Gibco, 
Scotland). The FBS-exosome depleted was obtained from Capricorn 
Scientific GmbH (Germany). Medium of cells was changed every 2~3 
days. 
2.3. EXO isolation and characterization 
The hEnSCs at 70–80% confluency were grown in DMEM/F12 þ
10% FBS-EXO depleted +1% pen/strep. After 24 h, hEnSCs supernatant 
was collect to apply for EXO isolation by differential centrifugation 
(300×g/10 min, 2000×g/10 min, 20000×g/30 min) that proceed with 
ultracentrifugation at 120000×g/120 min/4 ◦C (Beckman Coulter X- 
14R centrifuge). The hEnSCs EXO characterization assays including size 
distribution, morphology evaluation and CD63 immunoblotting was 
performed according to our recently published protocol [14]. 
2.4. Atorvastatin loading into EXO (AtoEXO) 
Ato was dissolved in DMSO and passed 0.2 μm filter. The Ato solution 
was diluted with culture medium at 10 μM and then 100 μg extracted 
EXOs were added to Ato solution. Four approaches for Ato incorporation 
into EXOs were evaluated: freeze-thaw cycles (Method I), sonication 
(Method II), diffusion (Method III) and conventional suspension (Method 
VI). For Method I, EX and Ato containing solution were exposed several 
times to the freeze-thawing cycle. To do this, the solution was exposed 
tree times rapidly to freezing and thawing at -80 ◦C and 37 ◦C, respec-
tively. Method II, contents of the EXO and Ato solution were place in ice 
bath and sonicated with voltage 500 V, frequency of 2 kHz and 20% 
power. During sonication operation, the pulse cycle was set for 4 s run 
and 2 s pause for 2 min. For Method III, sample incubation was per-
formed by addition of 0.1% tween-20 and incubation with gentle 
shaking on rotary shaker for 18 h at room temperature. Method VI, 
loading Ato in EXO without addition of tween-20 and just incubation. 
Indirect method was used to evaluate Ato loading into EXOs. The tubes 
containing EXOs and Ato were ultra-centrifuged for at 12000 g and 120 
min. The absorbance of supernatant was at 246 nm and the difference 
between absorbance of samples just before addition of EXOs and su-
pernatant correlated with the amount of loaded Ato in EXO using cali-
bration curve. 
2.5. AtoEXO characterization 
The various characterization methods were applied to evaluate the 
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quality of AtoEXO Nanoformulation. 
2.5.1. Size distribution analysis 
Hydrodynamic diameter of AtoEXO was studied by dynamic light 
scattering (DLS) assessments using a Zetasizer Nano ZS (Malvern In-
struments, Malvern, UK) as claimed by company. 
2.5.2. Morphology of EXOs 
To visualize AtoEXO morphology, scanning electron microscopy 
(SEM) were utilized. AtoEXO pellets were vortexed then were re- 
suspended in phosphate-buffered saline (PBS). The AtoEXO suspension 
10 μL was fixed in 2.5% paraformaldehyde. The process followed by 
sample dehydration with 75% ethanol, drying and finally covering with 
a thin layer of gold layer to analysis under SEM (QUANTA SEM system; 
FEI Company, Hillsboro, OR, USA). 
2.5.3. Immunoblotting of EXOs 
The effective immunoblotting of CD63 as a specific CD marker of 
EXO was performed on isolated EXOs and AtoEXOs. In detail, briefly, 
12% SDS-PAGE was prepared for exosomal total proteins that extracted 
using RIPA buffer (Radioimmuno Percipitation Assay). After that pro-
teins were transferred to nitrocellulose membrane, multi-steps including 
blocking with (5% milk and 0.05% tween-20 in PBS), incubation with 
primary anti-CD63 monoclonal antibody (Santa Cruz Biotechnology, 
Dallas, Texas, USA) for 2 h. Then, samples were washed in PBS and 
incubated with secondary horseradish peroxidase (HRP)-conjugated 
antibody (SinaClon, Tehran, Iran) for 2 h. The CD63 bands related to 
naive EXO and AtoEXO were detected using DAB solution. 
2.6. Release profile of Ato 
Time-courses for the diffusion of Ato from EXOs were measured as 
follows. Harvested AtoEXOs were placed in 10 mL PBS and mixed on a 
rotary shaker at 4 ◦C and the concentration of Ato remaining in the 
solution was analyzed at prescribed time points. In brief, AtoEXO solu-
tion was centrifuged at 120000 g and 120 min. Then, supernatant 1 mL 
was used for UV-measurement at 246 nm and equal volume fresh PBS 
was added to EXO solution and mixing of rotary was continued until 
168 h. The quantity of released Ato was normalized per initial degree of 
loading. 
2.7. EXO size stability 
The size stability of AtoEXOs was measured through size distribution 
measurement. For this, 50 μL AtoEXOs was suspended in 1 mL PBS and 
was shacked gently at physiological temperature until 30 days. The 
changes in size of AtoEXOs was measured using size distribution analysis 
and averaged. 
2.8. Cellular uptake of AtoEXOs 
The feasibility of cellular uptake of AtoEXOs within the intercellular 
filamentous structures of U87 cells were carry out using fluorescent la-
beling process. Briefly, 1, 1′-Dioctadecyl-3, 3, 3′, 3′-tetramethylindo-
carbocyanine perchlorate (DiI) dye solution was added to AtoEXOs 
suspension and incubated for 1 h under gentle shaking in physiological 
temperature. The nuclei of U87 cells were stained with DAPI (4′,6-dia-
midino-2-phenylindole; light blue) (Sigma-Aldrich) at 1 μM. The non- 
diffused DiI or DAPI from samples were removed through centrifuga-
tion and washing with PBS. 
2.9. Production of glioblastoma model and 3 D encapsulation 
In brief, the U87 cell line was cultured in T25 culture flasks con-
taining 5 mL of pre-warmed cell culture media (DMEM/F12 þ 10% FBS 
+ 1% pen/strep) at 37 ◦C, 5% CO2, 95% humidity. The U87 cells at 80% 
confluency were removed from T25 cell culture flask by trypsinization 
and suspension of cells were centrifuged at 300×g/10 min. The acquired 
U87 cells at density of 1 × 104 cells was placed on the surface of well- 
plate in hanging-drop method and incubated at physiological condi-
tion for 48 h to provide desirable U87 spheroid. The culture media was 
added and incubated for 48 h to provide desirable U87 spheroid. Then, 
prepared U87 spheroid was removed from surface of well via sterilized 
blade. Separately, 200 μL matrigel (Corning, Matrigel, UK) was poured 
on surface of well and after 30 min incubation, the prepared U87 
spheroid was placed on its surface and in following additional 200 μL 
matrigel poured on prepared matrix surface which resulted U87 
spheroid encapsulation in 3 D model of matrigel. 
2.10. MTT evaluation of U87 cells 
The U87 spheroid in 3D model of matrigel was incubated in DMEM/ 
F12 medium supplemented with concentrated free at 5, 10 μM and Ato 
loaded EXOs in same concentration of Ato was poured on wells until 72 
h. The MTT assay was used to measure anti-proliferation by MTT Kit 
(thiazolyl blue tetrazolium bromide; Sigma) on U87 spheroids as a 
glioblastoma tumor model. At the indicated time points, the cells were 
released from matrigel through incubation of specimens in collagenase 
A (1mg/mL) at 4 ◦C within 20 min. After washing cells with culture 
media, MTT solution 5 mg/mL was added into each well followed by 
incubation for 4 h. The medium was removed and insoluble purple 
formazan product was dissolved by dimethyl sulfoxide (DMSO) for 20 
min. The absorbance was measured by a microplate reader at 570 nm 
(EL340 Bio-Tek Instruments, Hopkinton, MA). 
2.11. Ki-67 expression of U87 cells 
The U87 cells were seeded in 6-well plates at a density of 2 × 104 
cells/cm2 and cultured for 72 h. The cells were fixed 4% para-
formaldehyde for 10 min and in 70% ethanol at room temperature. After 
that, the cells were divided in two parts. The first part of cells suspended 
in cold PBS containing fluorescein isothiocyanate conjugate-labeled 
anti-Ki-67 antibody (catalog No. 556026; BD Biosciences) and incu-
bated at 4 ◦C for 30 min. Then, treated cells were washed via PBS and 
were centrifuged to remove non-reacted fluorophore molecules. The 
fluorescence of labeled cells was measured using a BD Accuri U87 flow 
cytometer (BD Biosciences, CA, USA). 
2.12. Annexin-PI assay 
Likewise the Ki-67 expression test, theU87 cells were seeded well 
plates at a density of 2 × 104 cells/cm2 and in following treated by Atro 
and AtoEXOs substrates. After 72 h incubation, annexin-PI assay was 
used to detect the feasible percentage of U87 cells which induced in 
apoptosis phase. The second part of harvested U87 cells from were 
washed with PBS and stained with diluted Annexin V–FITC and propi-
dium iodide (PI), fluorophore in binding buffer for 30 min in the dark. 
Finally, U87 cells were washed with PBS and subjected to flow cytom-
etry technique using flow cytometer. 
2.13. TUNEL labeling for apoptosis 
The after fixation process of cell from matrigel, harvested cells were 
washed with 10 mM tris hydrochloride buffer and permeabilized with 
protein kinase 2% at 37 ◦C for 60 min. The cells were poured in TUNEL 
reaction mixture and incubated in physiological condition for 60 min, 
rinsed with PBS. The stained cells were observed by a light microscope 
at × 100 magnification for detecting TUNEL-positive cells. 
2.14. Quantitative real-time polymerase chain reaction 
RNA extraction and real-time polymerase chain reaction (RT-PCR) 
analysis was performed in order to define the expression level of 
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initiative and executive apoptosis genes. For this, trizol solution (Invi-
trogen, USA) was used to extract total RNA from U87 cells for each 
experimental conditions according to the manufacturer’s instructions. 
Afterward, cDNA was synthesized by Revert Aid first-strand cDNA 
synthesis kit (Thermo Scientific Fermentas, USA), according to the 
manufacturer’s instructions. Primers for real-time PCR were designed 
using Beacon Designer 7 software. The primer sequences information 
presented in Table 1. Quantitative RT-PCR (qRT-PCR) was performed on 
cDNAs using Rotor-Gene Q 2plex HRM platform real-time PCR system 
(Corbett Life Science). The relative expression levels of caspase 3, 8 and 
9 were evaluated in comparison with GAPDH as an endogenous control 
gene. Each 15 μL reaction volume was contained 7.5 μL of the concen-
trated 2 × SYBR green master mix (Invitrogen, USA), 1 μL of cDNA, and 
0.6 μL (10 ppm) of each pair of oligonucleotide primers. The RT-PCR 
reactions were done in duplicate. The PCR cycling began with an 
initial step of 95 ◦C for 10 min followed by 35 cycles of 95 ◦C for 20 s, 57 
◦C for 20 s and 72 ◦C for 15 s; then a melting curve was analyzed. Rotor- 
gene Q sequence detection system determined the threshold cycle (CT) 
values. Comparative threshold cycle (2− ΔΔCT) method was used in 
order to analyze the data. 
2.15. Statistical analysis 
All experiments were carried out in triplicate for each condition. The 
data are shown as means ± standard deviation (SD). Statistical analysis 
was done by Minitab 18 software (Minitab, Inc., State College, USA). 
Significant differences are expressed as *P < 0.05, **P < 0.01, and ns P >
0.05 in bar graphs. 
3. Results 
3.1. AtoEXO characterization 
The harvested EXO and AtoEXO analyzed by particle size measure-
ment, SEM, and western blot observations (Fig. 1). The obtained EXOs 
and AtoEXO possessed a spheroid-shape morphology with uniform and 
narrow size distribution in diameters of just about 30–150 nm which 
indicate appearance of all EXOs were consistent with previous studies 
[14,45] (Fig. 1A and B). Besides, western blotting analysis confirmed 
that hEnSCs vesicles and isolated AtoEXO nanoparticles were positive 
for CD63 protein (Fig. 1C). The CD63 expression was highly expressed in 
isolated EXOs as well as AtoEXO nanoformulation. Meanwhile, expres-
sion of CD63 marker was not distinguishable in the supernatant of the 
isolated AtoEXO condition (Fig. 1C). The results proved that extracel-
lular vesicles from hEnSCs were indeed EXOs and these could be utilized 
as effective nano-biocarrier for the loading of Ato in it. These results are 
consistent with previous reports that EXOs derived from other cell 
sources [13,14,22–24]. 
3.2. Nanoformulation of Ato in AtoEXO production 
Drug encapsulation efficiency is an essential parameter for devel-
oping successful formulations and evaluating drug delivery potential of 
prepared biocarriers [46]. Therefore, we assessed the Ato encapsulation 
efficiency in EXOs. The loading capacity of Ato in EXOs in different 
conditions evaluated using UV–vis spectroscopy at 246 nm. Meanwhile, 
Ato encapsulation efficiency was lowest amount for freeze/thaw method 
about 10% (Fig. 2A). The Ato encapsulation was found to be highest at 
diffusion condition which sample was incubated in presences of tween at 
about 28% (Fig. 2A). The sonication and normal incubation methods 
had also moderate encapsulation efficacy at about 20% (Fig. 2A). It is 
expected that tween 20 promotes Ato compound diffusion and per-
meabilization from EXO transmembrane likewise its effects on cell 
membrane. This compound could remove cholesterol binds at exosomal 
membrane and create pores in exosomal lipid bilayer membrane which 
allows superior diffusion of Ato into the EXOs [47]. It is reported that 
using detergent tween helps in the extraction of drug from the EXOs by 
dissociating drug-EXO interaction [21]. The low release profile of 
loaded Ato in EXOs suggest that most of existed Ato inside of EXOs could 
not associated with their membranes (Fig. 2B). The average size of EXO 
is depended on cell type and is ranged from 30 to 200 nm [48–50]. The 
size of AtoEXO was slightly comparable with EXOs obtained from cells 
treated with naive EXO vehicle (Fig. 1A and B). Moreover, modulation of 
sustainable drug delivery is recognized as an influential factor for tumor 
treatment [51–53]. The Ato release profile from the EXO sample shown 
in Fig. 2B. The Ato was continuously released within 168 h from 
AtoEXO. The controlled release of Ato from AtoEXO with slightly fast 
release was about 50% in 48 h and this continuous controlled release 
was constant until 168 h at 75%. These results demonstrate the advan-
tage of using developed AtoEXO in cancer treatment due to the 
increasing time of drug release by an initial, slightly fast release and then 
a sustained release phase. The structure and size stability of Ato loaded 
EXOs at -20 ◦C over time was also investigated until 30 days. The size of 
EXOs shows quite stable form and did not change during extended time 
of incubation until 30 days which prove integration of Ato with EXOs 
(Fig. 2C). This could be related to hydrophobic property of Ato and lipid 
layer of EXOs. The uniform and stable size of AtoEXO demonstrates that 
Ato encapsulation and its hydrophobic characteristics resulted in feasi-
bility of AtoEXO [54–56]. 
In following AtoEXO uptake by U87 cells was evaluated to elaborate 
applicability of developed AtoEXO for growth tumor suppression. The 
uptake of AtoEXO observed in the recipient U87 cells after 1 h incuba-
tion which indicate intracellular accumulation of AtoEXO in cancer cell 
line (Fig. 2D). 
3.3. MTT assay 
To evaluate effect of EXO loaded with Ato on cell proliferation in 
glioblastoma models, we performed dose-response study as well as with/ 
without EXO carrier conditions for seeded U87 cell line. Fig. 3 shows the 
result of MTT assay and morphology of U87 cells. As can be seen, U87 
cell viability increased in control group (non-treated condition) by 
increasing time of culture. Most of glioblastoma cells remained viable 
after treatments in lower concentration of Ato content. An interesting 
point from Fig. 3 is that increasing Ato content at 10 μM decreases the 
U87 cell viability in a time-depended manner even for initial 24 h. More 
interestingly, incorporation of Ato in EXOs decreased significantly cell 
viability and it was continued during extended time of incubation until 
72 h (Fig. 3A and B). Moreover, cellular morphology changed from 
spindle shape to spheroid-shaped by incorporation of high concentration 
of free Ato and AtoEXO substrates. Recent studies demonstrate that Ato 
affects mitochondrial functions which has an important role in cell 
survival [57,58]. Increasing Ato content had a positive effect on 
decrease of U87 cell viability. The Ato had an important role as a 
cofactor in cellular physiology and function [57,58]. Its positive effect 
on the mitochondrial function of different kind of cells at adjacent 
concentrations has been reported [59]. Results showed that 5 and 10 μM 
concentration of Ato when combined with EXOs had synergistic cyto-
toxicity on glioblastoma cells, via inducing apoptosis and interfering 
with the cell cycle. 
Table 1 
Forward and reverse primers of genes used for RT-PCR experiments.  
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3.4. Ki-67 protein expression 
Degree of Ki-67 expression is highly responsible for cell proliferation 
in tumor cells and may more accurately help to define high-risk patients 
[60,61]. Therefore, anti-proliferative effects of AtoEXO was evaluated 
by flowcytometry for Ki-67 expression [62]. The U87 cells in control 
condition (non-treated cells) was expressed Ki-67 more 90% which 
shows proliferation potential of U87 cells in 3 D matrigel (Fig. 4A and B). 
The utilized free Ato and AtoEXO were able to inhibit U87 cell prolif-
eration as evidenced by a significant reduction in Ki-67 labeling index 
(Fig. 4A and B). Interestingly, AtoEXO showed more significant impact 
on cellular proliferation and Ki-67 expression index was lower than 11% 
for these conditions (Fig. 4A and B). Meanwhile, Ki-67 index was more 
than 21% for direct application of Ato in different concentrations 
(Fig. 4A and B). However, there was no significant difference between 
doses studied as far as inhibition of cell proliferation is concerned. The 
obtained results for Ki-67 index for experimental conditions were 
consistent with MTT assay and cellular growth inhibition (Fig. 3). The 
results proved that utilization of AtoEXO was highly effective in U87 cell 
growth suppression and could utilize this produced substrate for GBM 
tumor suppression. 
3.5. Annexin/PI and cell cycle 
It is well known that collapse of mitochondrial membrane is mainly 
induces cell apoptosis (programmed cell death) and mitochondrial 
membrane disruption results in releasing apoptogenic proteins which 
causes cell death [63]. In this study, we compared U87 cell apoptosis 
and necrosis that are induced by releasing of Ato from EXOs. The 
non-treated condition possessed lowest level of apoptosis and necrosis 
compared with free Ato and AtoEXO conditions. The non-treated U87 
cells with AtoEXO in matirgels shows total apoptosis 2.94% with early 
and late apoptosis 1.33% and 1.61% respectively. The viability of cells 
was significantly decreased in all experimental conditions treated with 
free Ato and AtoEXO which indicate effectiveness of Ato and EXOs to 
induce cellular apoptosis and decrease cell viability (Fig. 5) as obtained 
consistent results with MTT assay and Ki-67 measurement (Figs. 3 and 
4). The AtoEXO 10 μL displays highest level of apoptosis at 30.37% 
Fig. 1. Characterization of atorvastatin loaded exosome (AtoEXO). (A) Size distribution of prepared AtoEXO, (B) SEM microphotograph of AtoEXO and (C) western 
blot of isolated AtoEXO, EXO and supernatant media of AtoEXO (Supernatant). 
Fig. 2. The evaluation of produced AtoEXOs nanoformulation. (A) Permeation of Ato in EXOs, (B) controlled release of encapsulated Ato in EXOs until 168 h in-
cubation (C) size stability of AtoEXO at -20 ◦C and (D) cellular uptake of AtoEXO in U87 cells. 
V.T. Nooshabadi et al.                                                                                                                                                                                                                         
Biochemistry and Biophysics Reports 23 (2020) 100792
6
including early and late apoptosis 4.31% and 26.6% respectively 
(Fig. 5). Meanwhile, treatment of U87 cells with Ato 5 and 10 μL induces 
necrosis in 24.1% and 23.4% of the cells, respectively which was com-
parable with AtoEXO 5 μL at 19.5% of the cells. The significant higher 
late apoptotic effect of AtoEXO can be related to long term and a mod-
erate release of Ato as shown in Fig. 5. 
Fig. 3. Cell viability measurement (A) and microphotographs (B) of U87 spheroids in matrigel treated with free Ato at 5 and 10 μM (Ato 5 and Ato 10 respectively) 
and also AtoEXO at 5 and 10 μM (AtoEXO 5 and AtoEXO 10 respectively) at 72 h. 
Fig. 4. Ki-67 expression of U87 cells harvested from 3D matrigels after 72 h treatment with Ato and AtoEXO in different concentrations. (A) Flowcytometry assay to 
evaluate the effects of the Ato and AtoEXO. (B) Quantitative amount of Ki-67 expression of U87 cells. The U87 cells were harvested, stained with Ki-67-FITC (FL-I) 
and analyzed by the flow cytometry. The statistical difference in the Ki-67 level was compared between among all groups. 
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Fig. 5. Flowcytometry assay to evaluate the effects of the free Ato and AtoEXO on the U87 cell apoptosis induction. (A) shows the histograms (B) (B) Quantitative 
amounts of necrotic, apoptotic and live cells. U87 cells were harvested from 2 D culture dish, free Ato and AtoEXO conditions after 72 h incubation and stained with 
Annexin V-FITC (FL-I) and PI for analyzing by the flow cytometry. 
Fig. 6. TUNEL staining of U87 cells in 3D matrigel model and (B) quantifying degrees of apoptotic cells (C) Expression level of caspase 3, caspase 8, for caspase 9 for 
U87 cells treated by Ato and AtoEXO in different concentrations. TUNEL assay was performed to quantify the apoptotic cells in different groups. The quantification of 
the apoptotic cells was determined and shown in the diagram. The proportion of apoptotic-positive cells significantly increased in AtoEXO 5 and 10 samples when 
compared with those of other experimental groups. 
V.T. Nooshabadi et al.                                                                                                                                                                                                                         
Biochemistry and Biophysics Reports 23 (2020) 100792
8
3.6. Apoptosis protein analysis 
Apoptosis is a main mechanism regarding the cell fate and possibility 
for tumor progression, since relative amounts of anti- and pro survival 
signals will be controlled whether the cell undergoes cell death and 
plays a critical role in cancer initiation and progression or not [64–66]. 
We have measured several family of proteins includes apoptosis-related 
molecules including tunnel as well as caspase 3, caspase 8 and caspase 9 
for 3 D cellular tumor spheroid which were exposed to AtoEXO for 72 h. 
Results showed that significantly altered the expression mRNA levels of 
these genes in U87 cell line (Fig. 6 A and B). The TUNEL assay (TUNEL 
Assay Kit, ab66110) was utilized to determine if the administration of 
different concentration of free Ato and AtoEXO enhances the apoptosis 
of the cells. The number of apoptotic-positive cells was counted in 5 
high-power fields ( × 400 magnification) and the mean percentage of 
apoptotic cells was reported. The proportion of apoptotic-positive cells 
in the AtoEXO 5 and AtoEXO 10 groups was significantly higher than 
that in the free Ato 5 and 10 as well as control group respectively (Fig. 6 
A). The proportion of apoptotic-positive cells between free drug (Ato 5 
and 10 groups) and the control group was also significant (p < 0.05). 
The pro-apoptotic gene caspase 8 and 9 as an extrinsic and intrinsic 
cascades [67], respectively and another marker of apoptosis caspase 3 
were significantly upregulated in all concentrations used free Ato and 
AtoEXO conditions (Fig. 6B). The expression degree of these genes was 
in maximum level for AtoEXO 10 condition compared with other 
experimental conditions (Fig. 6B). It is most likely that free Ato and 
AtoEXO induce apoptosis by elevating their upstream signal where cy-
tochrome C interacts with caspases signaling pathways [68]. The indi-
rect delivery of anti-cancer drug using EXO in order to induce the 
apoptotic process demonstrates more efficient activity to control cancer 
cell growth through up regulation of pro-apoptotic and apoptosis 
pathways (Fig. 6A and B). Caspases are key factors in the execution of 
apoptosis. Mitochondrial pathways and death receptor-mediated path-
ways are two main apoptosis pathways, when caspase 8 protease is 
activated, it activates caspase 3 to trigger apoptosis [69,70]. Therefore, 
both pathways converge at activation of the effector caspases. Besides, 
the cleavage of caspase 9 was indicative of apoptotic cell death. 
Whereas, there is some crosstalk between the activated caspase 8 can 
also trigger activation of caspase 9 [68,70]. Therefore, we could 
demonstrate anti-cancer toxicity of AtoEXOs in U87 cancer cell line via 
the caspase cascade of pro-apoptotic and apoptosis pathways. Hence, 
AtoEXOs represent a potentially biocompatible and applicable 
nano-carrier for sustainable drug delivery. These finding support the 
potential of AtoEXOs for targeted brain drug delivery in the treatment of 
brain cancer. 
4. Conclusion 
In summary, the present study demonstrates feasibility of EXO 
isolation from hEnSCs which this could be used as a bioactive drug 
nanocarrier to load Ato with high loading efficiency for inhibition of 
glioblastoma growth. The AtoEXOs showed uniform size distribution, 
stable structure and controlled release of Ato during extended time of 
incubation. Besides, the AtoEXO could be taken up by U87 cells and 
induce glial cell death. The AtoEXO inhibited the glial cell line growth 
and proliferation by minimizing cell density and viable cell as well as 
decreasing expression of Ki-67 protein. Moreover, upregulation of 
apoptosis genes proves that AtoEXO would provide a promising sus-
tainable drug delivery vehicle for tumor-targeted treatment in further 
study. 
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